Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy
August 18, 2020 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced a $1 million grant and four-year partnership with the HCM Registry (HCMR), a...
Cytokinetics Reports Second Quarter 2020 Financial Results
August 06, 2020 16:00 ET
|
Cytokinetics, Incorporated
Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capitalto Support Commercial Development and Pipeline...
Cytokinetics to Announce Second Quarter Results on August 6, 2020
July 23, 2020 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2020 at...
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 21, 2020 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously announced underwritten public offering of...
Cytokinetics Announces Pricing of Public Offering of Common Stock
July 16, 2020 23:32 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 7,291,667 shares of its...
Cytokinetics Announces Proposed Public Offering of Common Stock
July 15, 2020 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $150,000,000 of shares...
Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today’s Virtual Investor & Analyst Day
July 15, 2020 07:30 ET
|
Cytokinetics, Incorporated
Topline Results from GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil, Cardiac Myosin Activator, Expected in Q4 Licensing Collaboration and Royalty Monetization Deals with Xi Jing...
Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
July 14, 2020 07:30 ET
|
Cytokinetics, Incorporated
$250 Million in Committed Capital to Cytokinetics;Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing Pharmaceuticals to Develop & Commercialize in China ...
Cytokinetics Announces Participation in the Launch of Kainomyx, Inc. Focused to the Treatment of Parasitic Diseases
July 13, 2020 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is participating in the launch of Kainomyx, Inc., a new...
Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
July 01, 2020 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a Virtual Investor and Analyst Day on Wednesday, July 15,...